NCT00735553.

Methods	Randomised controlled trial
Participants	Premenopausal women with uterine fibroids and heavy menstrual bleeding
Interventions	Telapristone acetate 25 mg vs 50 mg vs placebo
Outcomes	To determine the efficacy of 50 mg Proellex vs placebo in the treatment of participants with symptomatic uterine fibroids from baseline to month 4 as determined by scoring changes in the pictorial blood loss assessment chart (PBAC)
Notes	Protocol NCT00735553 in clinicaltrials.gov of telapristone acetate 25 mg vs 50 mg vs placebo. No results in database nor in published literature. States trial was terminated